Search Database

Name

Enfortumab vedotin

Alternate Names

None

Abbreviations

None

Category

Biologic therapy (BRM, immunotherapy)

Subcategory

Antibody-drug conjugate

NSC Number

None

Primary Site

Bladder

Histology

None

Remarks

March 30, 2018: FDA has granted Breakthrough Therapy Designation to enfortumab vedotin, an antibody-drug conjugate, for patients with locally advanced or metastatic urothelial cancer who were previously treated with checkpoint inhibitors.

Coding

This drug should be coded
Glossary